Acorda Therapeutics Inc. (Nasdaq: ACOR) halted new enrollments in its Phase 3 study of tozadenant to treat Parkinson's disease after five deaths. Shares of the biopharmaceutical plummeted $11.20 to close at $17.00.
Acorda Therapeutics halts study enrollment
November 15, 2017 at 17:37 PM EST
